SEARCH:   Advanced

Blood, 15 November 2003, Vol. 102, No. 10, pp. 3584-3586. Prepublished online as a Blood First Edition Paper on July 24, 2003; DOI 10.1182/blood-2003-04-1032. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-04-1032v1 102/10/3584    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Maciejewski, J. P. Articles by Young, N. S. Search for Related Content PubMed PubMed Citation Articles by Maciejewski, J. P. Articles by Young, N. S. Related Collections Hematopoiesis and Stem Cells Red Cells Transfusion Medicine Immunotherapy Brief Reports Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  HEMATOPOIESIS Brief report Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia Jaroslaw P. Maciejewski, Elaine M. Sloand, Olga Nunez, Carol Boss, and Neal S. Young From the Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD. In contrast to severe aplastic anemia (sAA), the appropriate management of patients with moderate pancytopenia is unclear. In this study, we examined the efficacy of a humanized monoclonal antibody recognizing interleukin-2 receptor (daclizumab), which has proven to be a successful immunosuppressive agent in solid organ and bone marrow transplantation. We treated 17 patients with moderate aplastic anemia (mAA) with 1 mg/kg every 2 weeks for 3 months. mAA was defined as depression of 2 of the 3 blood counts: absolute neutrophil count 1200/mm3 or less, platelet count 70 000/mm3 or less, hemoglobin level 8.5 g/dL or lower, and absolute reticulocyte count 60 000/mm3 or less. The primary end point of our protocol was a hematologic response in at least one affected peripheral blood value. Daclizumab had little toxicity. Six of the 16 (38%) evaluable patients responded to treatment. Two patients with previously chronic disease showed complete return of normal counts, which were sustained for more than 2 years following treatment. Four patients had single-lineage responses. Two previously transfusion-dependent patients became transfusion independent; one patient with many neutropenia-related infections had a normal neutrophil count following treatment. Daclizumab appears safe; its efficacy in this pilot protocol suggests that expanded study of this monoclonal antibody in immune-mediated bone marrow failure syndrome is warranted. (Blood. 2003; 102:3584-3586) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. T. Snyder, J. Shen, H. Azmi, J. Hou, D. H. Fowler, and J. A. Ragheb Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine production Blood, June 15, 2007; 109(12): 5399 - 5406. [Abstract] [Full Text] [PDF] N. S. Young, R. T. Calado, and P. Scheinberg Current concepts in the pathophysiology and treatment of aplastic anemia Blood, October 15, 2006; 108(8): 2509 - 2519. [Abstract] [Full Text] [PDF] M. Hall and T. M. Hagemann Successful desensitization to antithymocyte globulin in a child with aplastic anemia. Am. J. Health Syst. Pharm., September 1, 2006; 63(17): 1633 - 1636. [Full Text] [PDF] E. M. Sloand, P. Scheinberg, J. Maciejewski, and N. S. Young Brief Communication: Successful Treatment of Pure Red-Cell Aplasia with an Anti-Interleukin-2 Receptor Antibody (Daclizumab) Ann Intern Med, February 7, 2006; 144(3): 181 - 185. [Abstract] [Full Text] [PDF] J. Marsh Making Therapeutic Decisions in Adults with Aplastic Anemia Hematology, January 1, 2006; 2006(1): 78 - 85. [Abstract] [Full Text] [PDF] S. J. Lemery, K. F. More, N. S. Young, and E. M. Sloand Daclizumab-Associated Erythroderma Is Associated with Rebound Increases in CD25-Positive CD4 Cells Following Treatment of Aplastic Anemia and Pure Red Cell Aplasia. Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 1042 - 1042. [Abstract] G. C. Bagby, J. M. Lipton, E. M. Sloand, and C. A. Schiffer Marrow Failure Hematology, January 1, 2004; 2004(1): 318 - 336. [Abstract] [Full Text] [PDF] W. Zeng, G. Chen, S. Kajigaya, O. Nunez, A. Charrow, E. M. Billings, and N. S. Young Gene expression profiling in CD34 cells to identify differences between aplastic anemia patients and healthy volunteers Blood, January 1, 2004; 103(1): 325 - 332. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020